EYP-1901 for Retinal Exudative Diseases - Summary - MDSpire

EYP-1901 for Retinal Exudative Diseases

  • By

  • Ashkan M. Abbey

  • May 29, 2026

Share

Objective:

To evaluate the efficacy and safety of EYP-1901 in treating retinal exudative diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

Key Findings:
  • EYP-1901 met primary endpoint in DAVIO 2, showing non-inferiority to aflibercept based on BCVA change.
  • Over 85% of EYP-1901-treated patients had stable or improved vision at six months.
  • In VERONA, EYP-1901 showed extended time to first supplemental treatment compared to aflibercept.
  • EYP-1901 demonstrated early and sustained vision improvements in DME patients.
Interpretation:

Limitations:
  • EYP-1901 is still investigational and not authorized for sale.
  • Long-term safety and efficacy data are pending from ongoing phase 3 trials.
Conclusion:

Original Source(s)

EYP-1901 for Retinal Exudative Diseases

  • by Ashkan M. Abbey

  • May 29, 2026

Related Content

Anti-VEGF Gains Ground in PDR

Brolucizumab challenges laser procedure in proliferative diabetic retinopathy management

  • May 28, 2026

  • 4 min
Myopia Management: Treat the Growing Eye, Not Just the Prescription

When to start, what to measure, how to monitor, and when to adjust course

Accelerating Peer Learning in Eye Care

Lumenis launches peer-to-peer learning program aimed at developing practical strategies for modern-day practice

  • May 27, 2026

  • 2 min